Shares of Akebia Therapeutics Inc (NASDAQ: AKBA), engaged in the business of developing therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, recorded over 15.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. AKBA was among the top performers in the U.S. healthcare sector after gaining 17.8% and closed at $12.21, Wednesday. Recently, the company announced positive top-line results from its phase 2b study of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease. During the past 5-trading sessions, AKBA gained 13.9% with daily average trading volumes of 339,657 shares, while the stock fell by 39.4% during the past one month with daily average trading volumes of 272,458 shares.
Company Description:
Akebia Therapeutics, Inc. (NASDAQ: AKBA) manufactures biopharmaceutical products. The company develops and distributes novel therapeutics based on the biology of hypoxia inducible factor (HIF) for patients with kidney diseases. Akebia Therapeutics serves customers in the U.S.
1-Year Stock Chart:
Source: Bloomberg
